|Last Price$50.04||Day Change (%)-0.44%|
|Open Price$50.19||Day Change ($)-0.22|
|Day Range49.75–50.37||52-Week Range44.37–57.49|
As of Mon 09/15/2014 05:46 PM EST | USD
European Commission Approves Bristol-Myers Squibb ’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
Fed Presidents Lockhart And Fisher Were Active Personal Asset Traders In 2013
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
U.S. Hot Stocks: Hot Stocks to Watch
BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi
Research and Markets: Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014
There is more competition among dividend-growth funds, making it harder to truly stand out.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.